Robert Tauber

Robert Tauber

Auto-generated profile, based on publicly available information

Robert Tauber

Klinik und Poliklinik für Urologie, TUM Universitätsklinikum Rechts der Isar, Technische Universität München, München, Deutschland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in European Urology
Verified
Journal Article
Closed access
BFBenedikt Feuerecker
Benedikt Feuerecker
RTRobert Tauber
Robert Tauber
KKKarina Knorr
Karina Knorr
MHMatthias Heck
Matthias Heck
ABAli Beheshti
Ali Beheshti
MEMatthias Eiber
Matthias Eiber

1 August 2020 in European Urology
Verified
Journal Article
Closed access
AGAndrei Gafita
Andrei Gafita
WFWolfgang P. Fendler
Wolfgang P. Fendler
WHWang Hui
Wang Hui
SSShahneen Sandhu
Shahneen Sandhu
MWManuel Weber
Manuel Weber
MHMichael S. Hofman
Michael S. Hofman

22 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FHFelix Harder
Felix Harder
KWKilian Weiss
Kilian Weiss
TAThomas Amiel
Thomas Amiel
JPJohannes M. Peeters
Johannes M. Peeters
RTRobert Tauber
Robert Tauber
RBRickmer Braren
Rickmer Braren
Background: To assess the performance of prospectively accelerated and deep learning (DL) reconstructed T2-weighted (T2w) imaging in volunteers and patients with histologically proven prostate cancer (PCa). Methods: Prospectively undersampled T2w datasets were acquired with acceleration factors of 1.7 (reference), 3.4 and 4.8 in 10 healthy volunteers and 23 patients with histologically proven PCa. Image reconstructions using compressed SENSE (C-SENSE) and a combination of C-SENSE and DL-based artificial intelligence (C-SENSE AI) were analyzed. Qualitative image comparison was performed using a 6-point Likert scale (overall image quality, noise, motion artifacts, lesion detection, diagnostic certainty); the T2 and PI-RADS scores were compared between the two reconstructions. Additionally, quantitative image parameters were assessed (apparent SNR, apparent CNR, lesion size, line profiles). Results: All C-SENSE AI-reconstructed images received a significantly higher qualitative rating compared to the C-SENSE standard images. Analysis of the quantitative parameters supported this finding, with significantly higher aSNR and aCNR. The line profiles demonstrated a significantly steeper signal change at the border of the prostatic lesion and the adjacent normal tissue in the C-SENSE AI-reconstructed images, whereas the T2 and PI-RADS scores as well as the lesion size did not differ. Conclusion: In this prospective study, we demonstrated the clinical feasibility of a novel C-SENSE AI reconstruction enabling a 58% acceleration in T2w imaging of the prostate while obtaining significantly better image quality.

7 June 2022 in European Urology
Verified
Journal Article
Closed access
HSHannah Schäfer
Hannah Schäfer
SMSarah Mayr
Sarah Mayr
MBMaike Büttner-Herold
Maike Büttner-Herold
KKKarina Knorr
Karina Knorr
LSLisa Steinhelfer
Lisa Steinhelfer
RTRobert Tauber
Robert Tauber

16 September 2021 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
BFBenedikt Feuerecker
Benedikt Feuerecker
MCMaythinee Chantadisai
Maythinee Chantadisai
AAAnne Allmann
Anne Allmann
RTRobert Tauber
Robert Tauber
JAJakob Allmann
Jakob Allmann
MEMatthias Eiber
Matthias Eiber
Introduction: Radiohybrid prostate-specific membrane antigen (rhPSMA)-ligands allow for labelling with 18F and radiometals for endoradiotherapy. rhPSMA-7.3 is designated as lead compound with promising preclinical data for 177Lu-rhPSMA-7.3 indicating higher tumor uptake compared with 177Lu-PSMA-I&T. In this retrospective analysis we compared pre-therapeutic clinical dosimetry of both PSMA-ligands. Methods: Six mCRPC patients underwent both 177Lu-rhPSMA-7.3 and 177Lu-PSMA-I&T pre-therapeutic dosimetry. Whole-body scintigraphy was performed at 1h, 4h, 24h, 48h and 7d post injection. Regions of interest (ROI) covering the whole body, organs, bone marrow and tumor lesions per patient were drawn. Absorbed doses for individual patients and pre-therapeutic applications were calculated using OLINDA/EXM. To facilitate comparison of both ligands we introduced the therapeutic index (TI) defined as ratio of mean pre-therapeutic doses to tumor lesions over relevant organs-at-risk. Results: Mean whole-body pre-therapeutic effective doses were 0.12±0.07 vs. 0.05±0.03 Sv/GBq and mean absorbed organ doses were e.g. 1.65±0.28 vs. 0.73±0.18 Gy/GBq for the kidneys; 0.19±0.09 vs. 0.07±0.03 Gy/GBq for the liver and 2.35±0.78 vs. 0.80±0.41 Gy/GBq for the parotid, for the bone marrow 0.67±0.62 vs. 0.30±0.27 Gy/GBq for 177Lu-rhPSMA-7.3 vs. 177Lu-PSMA-I&T, respectively. Tumor lesions received a mean absorbed doses of 6.44±6.44 vs. 2.64±2.24 Gy/GBq for 177Lu-rhPSMA-7.3 vs. 177Lu-PSMA-I&T, respectively. The mean TI(kidney) and TI(bone_marrow) were 3.7±2.2 vs. 3.6±2.2 and 15.2±10.2 vs. 15.1±10.2, for 177Lu-rhPSMA-7.3 vs. 177Lu-PSMA-I&T, respectively. Conclusion: Pre-therapeutic clinical dosimetry confirmed preclinical results with 2-3 times higher mean absorbed doses for tumors of 177Lu-rhPSMA-7.3 compared to 177Lu-PSMA-I&T. Absorbed doses to normal organs also tended to be higher for 177Lu-rhPSMA-7.3 resulting overall in a similar average TI for both radiopharmaceuticals with considerable inter-patient variability. 177Lu-rhPSMA-7.3 holds promise for similar therapeutic efficacy as 177Lu-PSMA-I&T at lower amounts of injected activity simplifying radiation safety measurements (especially for large patient numbers and/or dose escalation regimes).

15 June 2023 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
RTRobert Tauber
Robert Tauber
KKKarina Knorr
Karina Knorr
MRMargitta Retz
Margitta Retz
IRIsabel Rauscher
Isabel Rauscher
SGSonia Grigorascu
Sonia Grigorascu
TLThomas Langbein
Thomas Langbein
177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new treatment option for metastatic castration-resistant prostate cancer (mCRPC). Its low toxicity profile favors use in elderly patients or in patients with critical comorbidities. The purpose of this analysis was to evaluate the efficacy and safety of [177Lu]-PSMA RLT in mCRPC patients at least 80 y old. Methods: Eighty mCRPC patients at least 80 y old underwent [177Lu]-PSMA-I&T RLT and were retrospectively selected. The patients were previously treated by androgen receptor–directed therapy, received taxane-based chemotherapy, or were chemotherapy-ineligible. The best prostate-specific antigen (PSA) response was calculated, as well as clinical progression-free survival (cPFS) and overall survival (OS). Toxicity data were acquired until 6 mo after the last treatment cycle. Results: Of 80 patients, 49 (61.3%) were chemotherapy-naïve and 16 (20%) had visceral metastases. The median number of previous mCRPC treatment regimens was 2. In total, 324 cycles (median, 4 cycles; range, 1–12) with a median cumulative activity of 23.8 GBq (interquartile range, 14.8–42.2) were applied. A PSA decline of 50% was achieved in 37 (46.3%) patients. Chemotherapy-naïve patients showed higher 50% PSA response rates than chemotherapy-pretreated patients (51.0% vs. 38.7%, respectively). Overall, median cPFS and OS were 8.7 and 16.1 mo, respectively. The median cPFS and OS of chemotherapy-naïve patients were significantly longer than those of chemotherapy-pretreated patients (10.5 vs. 6.5 mo and 20.7 vs. 11.8 mo, respectively, P < 0.05). A lower hemoglobin level and higher lactate dehydrogenase level at baseline were independent predictors of shorter cPFS and OS. Treatment-emergent grade 3 toxicities were anemia in 4 patients (5%), thrombocytopenia in 3 patients (3.8%), and renal impairment in 4 patients (5%). No nonhematologic grade 3 and no grade 4 toxicities were observed. The most frequent clinical side effects were grade 1–2 xerostomia, fatigue, and inappetence. Conclusion: [177Lu]-PSMA-I&T RLT in mCRPC patients at least 80 y old is safe and effective, comparable to previously published data on non–age-selected cohorts with a low rate of high-grade toxicities. Chemotherapy-naïve patients showed a better and longer response to therapy than taxane-pretreated patients. [177Lu]-PSMA RLT seems to be a meaningful treatment option for older patients. Visual Abstract